Clinical Trial Update: A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating TQ05105 in combination with TQB3909 for myelofibrosis was terminated. No results are provided in the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• TQ05105
• TQB3909

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Myelofibrosis | Phase 1, Phase 2 | Status: TERMINATED